43.92
-1.06 (-2.35%)
| Previous Close | 44.97 |
| Volume | 75,933 |
| Price / Earnings (Forward) | 9.82 |
| Price / Sales | 1.84 |
| Price / Book | 1.10 |
| 52 Weeks Range |
| Profit Margin | 18.86% |
| Operating Margin (TTM) | 34.03% |
| Diluted EPS (TTM) | 4.29 |
| Quarterly Revenue Growth (YOY) | 7.10% |
| Quarterly Earnings Growth (YOY) | 1.40% |
| Total Debt/Equity (MRQ) | 56.91% |
| Current Ratio (MRQ) | 4.20 |
| Operating Cash Flow (TTM) | 251.52 M |
| Levered Free Cash Flow (TTM) | 188.69 M |
| Return on Assets (TTM) | 6.50% |
| Return on Equity (TTM) | 12.30% |
AIStockmoo Score
| Value 38% | -1.8 |
| AI Insight info | NA |
| Relative Valuation info | -5.0 |
| Financial Health info | 3.0 |
| Timing 38% | -1.1 |
| AI Technical info | NA |
| Technical Oscillators info | -2.5 |
| Technical Moving Averages info | 1.0 |
| Sentiment 25% | 0.0 |
| Analyst Consensus info | 0.0 |
| News Mood info | NA |
| Smart Money | NA |
| Insider Activity info | NA |
| Institutional Flow info | NA |
| Environment | ×1.15 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -4.0% |
| Pillar Agreement | ×1.25 |
| Not in score | |
| Price Volatility info | 1.8 |
| Final Score | -1.57 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Prestige Consumer Healthcare In | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| PBH | - | - | - | 1.10 |
| BHC | - | - | - | - |
| PRGO | - | 5.36% | - | 0.900 |
| EBS | - | - | - | 0.970 |
| RDY | - | 0.68% | - | 3.07 |
| TAK | - | 4.61% | - | 1.43 |
Select this tab to load the latest available analysis.
|
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige’s key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer’s Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 1.23% |
| % Held by Institutions | 108.15% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |